Sex Differences in Neurological Diseases

Sex Differences in the Central Nervous System

Volumn , Issue , 2015, Pages 297-323

  Sohrabji, Farida ^a   Jane Welsh, C ^b   Reddy, Doodipala Samba ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Epilepsy; Estrogen; Inflammation; Multiple sclerosis (MS); Progesterone; Stroke

Indexed keywords

EID: 84960824887     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802114-9.00012-3     Document Type: Chapter

References (193)

1. Abramsky O. Pregnancy and multiple sclerosis. Ann. Neurol. 1994, 36:S38-41.
2. Ajmo C.T., Vernon D.O., Collier L., Hall A.A., Garbuzova-Davis S., Willing A., Pennypacker K.R. The spleen contributes to stroke-induced neurodegeneration. J. Neurosci. Res. 2008, 86:2227-2234.
3. Alkayed N.J., Harukuni I., Kimes A.S., London E.D., Traystman R.J., Hurn P.D. Gender-linked brain injury in experimental stroke. Stroke 1998, 29:159-165. discussion 166.
4. Allen C.L., Bayraktutan U. Risk factors for ischaemic stroke. Int. J. Stroke 2008, 3:105-116.
5. Alley J., Khasabov S., Simone D., Beitz A., Rodriguez M., Njenga M.K. More severe neurologic deficits in SJL/J male than female mice following Theiler's virus-induced CNS demyelination. Exp. Neurol. 2003, 180:14-24.
6. Alonso A., Jick S., Olek M.J., Ascherio A., Jick H., Hernan M.A. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch. Neurol. 2005, 62:1362-1365.
7. Anderson D.W., Ellenberg J.H., Leventhal C.M., Reingold S.C., Rodriguez M., Silberberg D.H. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 1992, 31:333-336.
8. Arnold A.P., Chen X. What does the "four core genotypes" mouse model tell us about sex differences in the brain and other tissues?. Front. Neuroendocrinol. 2009, 30:1-9.
9. Bäckström T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol. Scand. 1976, 54:321-347.
10. Bäckström T., Zetterlund B., Blom S., Romano M. Effect of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol. Scand. 1984, 69:240-248.
11. Bake S., Sohrabji F. 17β-Estradiol differentially regulates blood-brain barrier permeability in young and aging female rats. Endocrinol. 2004, 145:5471-5475.
12. Bazan A.C., Montenegro M.A., Cendes F., Min L.L., Guerreiro C.A. Menstrual cycle worsening of epileptic seizures in women with symptomatic focal epilepsy. Arq. Neuropsiquiatr. 2005, 63(3B):751-756.
13. Bebo B.F., Vandenbark A.A., Offner H. Male SJL mice do not relapse after induction of EAE with PLP 139-151. J. Neuroci. Res. 1996, 45:680-689.
14. Bebo B.F., Schuster J.C., Vandenbark A.A., Offner H. Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. J. Neurosci. Res. 1998, 52:420-426.
15. Bebo B.F., Adlard K., Schuster J.C., Unsicker L., Vanderbark A.A., Offner H. Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. J. Neurosci. Res. 1999, 55:432-440.
16. Bebo B.F., Fyfe-Johnson A., Adlard K., Beam A.G., Vandenbark A.A., Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol. 2001, 166:2080-2089.
17. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.K. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
18. Bonuccelli U., Melis G.B., Paoletti A.M., Fioretti P., Murri L., Muratorio A. Unbalanced progesterone and estradiol secretion in catamenial epilepsy. Epilepsy Res. 1989, 3:100-106.
19. Brann D.W., Dhandapani K., Wakade C., Mahesh V.B., Khan M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007, 72:381-405.
20. Brann D., Raz L., Wang R., Vadlamudi R., Zhang Q. Oestrogen signalling and neuroprotection in cerebral ischaemia. J. Neuroendocrinol. 2012, 24:34-47.
21. Bushnell C.D. Stroke in women: risk and prevention throughout the lifespan. Neurol. Clin. 2008, 26(4):1161-1176.
22. Carver C.M., Reddy D.S. Neurosteroid interactions with synaptic and extrasynaptic GABA-A receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology 2013, 230(2):151-188.
23. Chen Y., Langrish C.L., Mckenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 2006, 116:1317-1326.
24. Chesik D., De Kesyer J. Progesterone and dexamethasone differentially regulate the IGF-system in glial cells. Neurosci. Lett. 2010, 468:178-182.
25. Choi Y.C., Lee J.H., Hong K.W., Lee K.S. 17 Beta-estradiol prevents focal cerebral ischemic damages via activation of Akt and CREB in association with reduced PTEN phosphorylation in rats. Fundam. Clin. Pharmacol. 2004, 18:547-557.
26. Christensen J., Kjeldsen M.J., Anderson H., Friis M.L., Sidenius P. Gender differences in epilepsy. Epilepsia 2005, 46:956-960.
27. Cipolla M., Godfrey J., Wiegman M. The effect of ovariectomy and estrogen on penetrating brain arterioles and blood-brain barrier permeability. Microcirculation 2009, 16:685-693.
28. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
29. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 1998, 339:285-291.
30. Coomber B., Gibson C.L. Sustained levels of progesterone prior to the onset of cerebral ischemia are not beneficial to female mice. Brain Res. 2010, 1361:124-132.
31. Cottrell D.A., Kremenchutzky M., Rice G.P.A., Koopman W.J., Hader W., Bakerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999, 122:625-639.
32. Cottrell D.A., Kremenchutzky M., Rice G.P.A., Koopman W.J., Hader W., Baskerville J., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. Brain 1999, 122:625-639.
33. Craig C.R. Anticonvulsant activity of steroids: separability of anticonvulsant from hormonal effects. J. Pharmacol. Exp. Ther. 1966, 153:337-343.
34. Crawford D.K., Mangiardi M., Song B., Patel R., Du S., Sofroniew M.V., Voskhul R.R., Tiwari-Woodruff S.K. Estrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination. Brain 2010, 133:2999-3016.
35. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
36. De Butte-Smith M., Nguyen A.P., Zukin R.S., Etgen A.M., Colbourne F. Failure of estradiol to ameliorate global ischemia-induced CA1 sector injury in middle-aged female gerbils. Brain Res. 2007, 1153:214-220.
37. Dubal D.B., Wise P.M. Neuroprotective effects of estradiol in middle-aged female rats. Endocrinology 2001, 142:43-48.
38. Dubal D., Kashon M., Pettigrew L., Ren J., Finklestein S., Rau S., Wise P. Estradiol protects against ischemic injury. J. Cereb. Blood Flow Metab. 1998, 18:1253-1258.
39. El-Khayat H.A., Soliman N.A., Tomoum H.Y., Omran M.A., El-Wakad A.S., Shatla R. Reproductive hormonal changes and catamenial pattern in adolescent females with epilepsy. Epilepsia 2008, 49:1619-1626.
40. El-Sayed Y.Y. Obstetric and gynecologic care of women with epilepsy. Epilepsia 1998, 39(Suppl. 8):S17-S25.
41. Espinosa-García C., Vigueras-Villaseñor R.M., Rojas-Castañeda J.C., Aguilar-Hernández A., Monfil T., Cervantes M., Moralí G. Post-ischemic administration of progesterone reduces caspase-3 activation and DNA fragmentation in the hippocampus following global cerebral ischemia. Neurosci. Lett. 2013, 550:98-103.
42. Fang M.C., Singer D.E., Chang Y., Hylek E.M., Henault L.E., Jensvold N.G., Go A.S. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005, 112:1687-1691.
43. Fletcher J.M., Lalor S.J., Sweeney C.M., Tubridy N., Mills K.H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 2010, 162:1-11.
44. Fuller A., Yahikozawa H., So E.Y., Dal Canto M., Koh C.S., Welsh C.J., Kim B.S. Castration of male C57L/J mice increases susceptibility and estrogen treatment restores resistance to Theiler's virus-induced demyelinating disease. J. Neurosci. Res. 2007, 85:871-881.
45. Galea E., Santizo R., Feinstein D.L., Adamsom P., Greenwood J., Koenig H.M., Pelligrino D.A. Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport 2002, 13(11):1469-1472.
46. Gangisetty O., Reddy D.S. Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience 2010, 170:865-880.
47. Garay L., Deniselle M.C.G., Lima A., Roig P., De Nicola A.F. Effects of progesterone in the spinal cord of a mouse model of multiple sclerosis. J. Steroid Biochem. Mol. Biol. 2007, 107:228-237.
48. Gilad R., Sadeh M., Rapoport A., Dabby R., Lampl Y. Lamotrigine and catamenial epilepsy. Seizure 2008, 17:531-534.
49. Giraud S.N., Caron C.M., Pham-Dinh D., Kitabgi P., Nicot A.B. Estradiol inhibits ongoing autoimmune neuroinflammation and NFkB-dependent CCL2 expression in reactive astrocytes. Proc. Natl. Acad. Sci. USA 2010, 107:8416-8421.
50. Glendenning M.L., Lovekamp-Swan T., Schreihofer D.A. Protective effect of estrogen in endothelin-induced middle cerebral artery occlusion in female rats. Neurosci. Lett. 2008, 445:188-192.
51. Gold S.M., Voskuhl R.R. Estrogen and testosterone therapies in multiple sclerosis. Progress in Brain Research 2009, 239-251. Elsevier, New York. J. Verhaagen, E.M. Hol, I. Huitenga, J. Wijnholds, A.B. Bergen, G.J. Boer, F.S. Dick (Eds.).
52. González-Vidal M.D., Cervera-Gaviria M., Ruelas R., Escobar A., Moralí G., Cervantes M. Progesterone: protective effects on the cat hippocampal neuronal damage due to acute global cerebral ischemia. Arch. Med. Res. 1998, 29:117-124.
53. Harden C.L., Pennell P.B., Koppel B.S., et al. Management issues for women with epilepsy - focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009, 50:1247-1255.
54. Harrison N.L., Majewska M.D., Harrington J.W., Barker J.L. Structure-activity relationships for steroid interactions with the γ-aminobutyric acidA receptor complex. J. Pharmacol. Exp. Ther. 1987, 241:346-353.
55. Hauser W.A. Incidence and prevalence. Epilepsy: A Comprehensive Textbook 1997, 47-57. Lippincott-Raven Publishers, Philadelphia. J. Engel, T.A. Pedley (Eds.).
56. Hawk T., Zhang Y.Q., Rajakumar G., Day A.L., Simpkins J.W. Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res. 1998, 796:296-298.
57. Herzog A.G. Hormonal therapies: progesterone. Neurotherapeutics 2009, 6:383-391.
58. Herzog A.G., Klein P., Ransil B.J. Three patterns of catamenial epilepsy. Epilepsia 1997, 38:1082-1088.
59. Herzog A.G., Friedman M.N., Freund S., Pascual-Leone A. Transcranial magnetic stimulation evidence of a potential role for progesterone in the modulation of premenstrual corticocortical inhibition in a woman with catamenial seizure exacerbation. Epilepsy Behav. 2001, 2:367-369.
60. Herzog A.G., Harden C.L., Liporace J., Pennell P., Schomer D.L., Sperling M., Fowler K., Nikolov B., Shuman S., Newman M. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann. Neurol. 2004, 56:431-434.
61. Herzog A.G., Fowler K.M., Smithson S.D., Kalayjian L.A., Heck C.N., Sperling M.R., Liporace J.D., Harden C.L., Dworetzky B.A., Pennell P.B., Massaro J.M. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology 2012, 78(24):1959-1966. Progesterone Trial Study Group.
62. Hesdorffer D.C., Begley C.E. Surveillance of epilepsy and prevention of epilepsy and its sequelae: lessons from the Institute of Medicine report. Curr. Opin. Neurol. 2013, 26(2):168-173.
63. Hill K.E., Pigmans M., Fujinami R.S., Rose J.W. Gender variations in early Theiler's virus induced demyelinating disease: differential susceptibility and effects of IL-4, IL-10 and combined IL-4 with IL-10. J. Neuroimmunol. 1998, 85:44-51.
64. Hosie A.M., Wilkins M.E., Smart T.G. Neurosteroid binding sites on GABAA receptors. Pharmacol. Ther. 2007, 116:7-19.
65. Ishrat T., Sayeed I., Atif F., Stein D.G. Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res. 2009, 1257:94-101.
66. Jacobs M.P., Leblanc G.G., Brooks-Kayal A., Jensen F.E., Lowenstein D.H., Noebels J.L. Curing epilepsy: progress and future directions. Epilepsy Behav. 2009, 14:438-445.
67. Jacono J.J., Robinson J. The effects of estrogen, progesterone, and ionized calcium on seizures during the menstrual cycle in epileptic women. Epilepsia 1987, 28:571-577.
68. Jezierski M.K., Sohrabji F. Region- and peptide-specific regulation of the neurotrophins by estrogen. Mol. Brain Res. 2000, 85:77-84.
69. Jiang N., Chopp M., Stein D., Feit H. Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Res. 1996, 735:101-107.
70. Johnson A.B., Sohrabji F. Estrogen's effects on central and circulating immune cells vary with reproductive age. Neurobiol. Aging 2005, 26:1365-1374.
71. Jover-Mengual T., Miyawaki T., Latuszek A., Alborch E., Zukin R.S., Etgen A.M. Acute estradiol protects CA1 neurons from ischemia-induced apoptotic cell death via the PI3K/Akt pathway. Brain Res. 2010, 1321:1-12.
72. Kantarci O.H., Weinshenker B.G. Natural history of multiple sclerosis. Neurol. Clin. 2005, 23:17-38.
73. Kaplan P.W., Norwitz E.R., Ben Menachem E., Pennell P.B., Druzin M., Robinson J.N., Gordon J.C. Obstetric risks for women with epilepsy during pregnancy. Epilepsy Behav. 2007, 11:283-291.
74. Kapral M.K., Fang J., Hill M.D., Silver F., Richards J., Jaigobin C., Cheung A.M. Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke 2005, 36:809-814.
75. Kipp M., Amor S., Krauth R., Beyer C. Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender. Front. Neuroendocrinol. 2012, 33:1-16.
76. Kipp M., Beyer C. Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis. Front. Neuroendocrinol. 2009, 30:188-200.
77. Kirkman N.J., Libbey J.E., Wilcox K.S., White H.S., Fujinami R.S. Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia 2010, 51(3):454-464.
78. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
79. Kumon Y., Kim S.C., Tompkins P., Stevens A., Sakaki S., Loftus C.M. Neuroprotective effect of postischemic administration of progesterone in spontaneously hypertensive rats with focal cerebral ischemia. J. Neurosurg. 2000, 92:848-852.
80. Kurth F., Luders E., Sicotte N.L., Gaser C., Giesser B.S., Swerdloff R.S., Montag M.J., Voskuhl R.R., Mackenzie-Graham A. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Neuroimage Clin. 2014, 4:454-460.
81. Lai S.M., Duncan P.W., Dew P., Keighley J. Sex differences in stroke recovery. Prev. Chronic Dis. 2005, 2:A13.
82. Landgren S., Bäckström T., Kalistratov G. The effect of progesterone on the spontaneous interictal spike evoked by the application of penicillin to the cat's cerebral cortex. J. Neurol. Sci. 1978, 36:119-133.
83. Lélu K., Laffont S., Delpy L., Paulet P.E., Périnat T., Tschanz S.A., Pelletier L., Engelhardt B., Guéry J.C. Estrogen receptor α signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J. Immunol. 2011, 187:2386-2393.
84. Leon R.L., Li X., Huber J.D., Rosen C.L. Worsened outcome from middle cerebral artery occlusion in aged rats receiving 17b-estradiol. Endocrinology 2012, 153:3386-3393.
85. Liao S., Chen W., Kuo J., Chen C. Association of serum estrogen level and ischemic neuroprotection in female rats. Neurosci. Lett. 2001, 297:159-162.
86. Lipton H.L. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. Infect. Immun. 1975, 11:1147-1155.
87. Liu R1, Wen Y., Perez E., Wang X., Day A.L., Simpkins J.W., Yang S.H. 17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. Brain Res. 2005, 1060:55-61.
88. Liu R., Wang X., Liu Q., Yang S.H., Simpkins J.W. Dose dependence and therapeutic window for the neuroprotective effects of 17beta-estradiol when administered after cerebral ischemia. Neurosci. Lett. 2007, 415:237-241.
89. Liu F., Yuan R., Benashski S.E., McCullough L.D. Changes in experimental stroke outcome across the life span. J. Cereb. Blood Flow Metab. 2009, 29:792-802.
90. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
91. Logothetis J., Harner R., Morrel F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology 1959, 9:352-360.
92. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesion: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
93. Manwani B., Liu F., Xu Y., Persky R., Li J., McCullough L.D. Functional recovery in aging mice after experimental stroke. Brain. Behav. Immun. 2011, 25:1689-1700.
94. Manwani B., Liu F., Scranton V., Hammond M.D., Sansing L.H., McCullough L.D. Differential effects of aging and sex on stroke induced inflammation across the lifespan. Exp. Neurol. 2013, 249:120-131.
95. Manwani B., Bentivegna K., Benashski S.E., Venna V.R., Xu Y., Arnold A.P., McCullough L.D. Sex differences in ischemic stroke sensitivity are influenced by gonadal hormones, not by sex chromosome complement. J. Cereb. Blood Flow Metab. 2014, 35(2):221-229.
96. Marriott L.K., Hauss-Wegrzyniak B., Benton R.S., Vraniak P.D., Wenk G.L. Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation. Behav. Neurosci. 2002, 116:902-911.
97. McClain M.A., Gatson N.N., Powell N.D., Papenfuss T.L., Gienapp I.E., Song F., Shawler T.M., Kithcart A., Whitacre C.C. Pregnancy suppresses experimental autoimmune encephalomyelitis through immunoregulatory cytokine production. J. Immunol. 2007, 179:8146-8152.
98. McCullough L.D., Alkayed N.J., Traystman R.J., Williams M.J., Hurn P.D. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke 2001, 32:796-802.
99. Morales L.B.J., Loo K.K., Liu H., Peterson C., Tiwari-Woodruff S., Voskuhl R.R. Treatment with an estrogen receptor - a ligand is neuroprotective in experimental autoimmune encephalomyelitis. Neurobiol. Dis. 2006, 26:6823-6833.
100. Moralí G., Montes P., Hernández-Morales L., Monfil T., Espinosa-García C., Cervantes M. Neuroprotective effects of progesterone and allopregnanolone on long-term cognitive outcome after globalcerebral ischemia. Restor. Neurol. Neurosci. 2011, 29:1-15.
101. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003, 44(Suppl. 4):11-20.
102. Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front. Biosci. 2009, 14:4477-4515.
103. Noonan C.W., Kathman S.J., White M.C. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002, 58(1):136-138.
104. Nordell V.L., Scarborough M.M., Buchanan A.K., Sohrabji F. Differential effects of estrogen in the injured forebrain of young adult and reproductive senescent animals. Neurobiol. Aging 2003, 24:733-743.
105. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
106. Offner H., Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann. NY Acad. Sci. 2006, 1089:343-372.
107. Okuda Y., Okuda M., Bernard C.C. Gender does not influence the susceptibility of C57Bl/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol. Lett. 2002, 81:25-29.
108. Olsen T.S., Andersen K.K. Female survival advantage relates to male inferiority rather than female superiority: a hypothesis based on the impact of age and stroke severity on 1-week to 1-year case fatality in 40,155 men and women. Gend. Med. 2010, 7:284-295.
109. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., Ebers G.C. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006, 5:932-936.
110. Ozacmak V.H., Sayan H. The effects of 17beta estradiol, 17alpha estradiol and progesterone on oxidative stress biomarkers in ovariectomized female rat brain subjected to global cerebral ischemia. Physiol. Res. 2009, 58:909-912.
111. Palaszynski K.M., Liu H., Loo K.K., Voskuhl R.R. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J. Neuroimmunol. 2004, 149:84-89.
112. Palaszynski K.M., Loo K.K., Ashouri J.F., Liu H., Voskuhl R.R. Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J. Neuroimmunol. 2004, 146:144-152.
113. Papenfuss T.L., Roger C.J., Glenapp I., Yurris M., McClain M., Damico N., Valo J., Song F., Whitacre C.C. Sex differences on experimental autoimmune encephalomyelitis in multiple mouse strains. J. Neuroimmunol. 2004, 150:59-69.
114. Park S.K., Kim J.M., Kim J.H., Cheong J.H., Bak K.H., Kim C.H. Aneurysmal subarachnoid hemorrhage in young adults: a gender comparison study. J Clin. Neurosci. 2008, 15:389-392.
115. Pitkänen A., Immonen R.J., Gröhn O.H., Kharatishvili I. From traumatic brain injury to posttraumatic epilepsy, what animal models tell us about the process and treatment options. Epilepsia 2009, 50(Suppl. 2):21-29.
116. Polanczyk M.J., Hopke C., Huan J., Vandenbark A.A., Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J. Neuroimmunol. 2005, 170:85-92.
117. Quigg M., Smithson S.D., Fowler K.M., Sursal T., Herzog A.G. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology 2009, 73:223-227. and the Progesterone Trial Study Group.
118. Rangachari M., Nauermann N., Marty R.R., Dirnhofer S., Kurrer M.O., Komnenovic V., Penninger J.M., Eriksson U. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J. Exp. Med. 2006, 203:2009-2019.
119. Reddy D.S. Anticonvulsant activity of the testosterone-derived neurosteroid 3α-androstanediol. Neuroreport 2004, 15:515-518.
120. Reddy D.S. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol. Neuroscience 2004, 129:195-207.
121. Reddy D.S. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res. 2009, 85:1-30.
122. Reddy D.S., 2009. Steroid hormones and sex differences in seizure susceptibility. In: Schwartzkroin, P. (Ed.), Encyclopedia of Basic Epilepsy Research, vol. 1. Academic Press, Oxford, pp. 526-533.
123. Reddy D.S. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog. Brain Res. 2010, 186:113-137.
124. Reddy D.S. Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives. Expert Rev. Clin. Pharmacol. 2010, 3(2):183-192.
125. Reddy D.S. Neuroendocrine aspects of catamenial epilepsy. Horm. Behav. 2013, 63:254-266.
126. Reddy D.S. Role of hormones and neurosteroids in epileptogenesis. Front. Cell. Neurosci. 2013, 7(115):1-20.
127. Reddy D.S. Neurosteroids and their role in sex-specific epilepsies. Neurobiol. Dis. 2014, 72:198-209.
128. Reddy D.S., Jian K. The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors. J. Pharmacol. Exp. Ther. 2010, 334:1031-1041.
129. Reddy D.S., Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int. J. Mol. Sci. 2013, 14(9):18284-18318.
130. Reddy D.S., Mohan A. Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. J. Neurosci. 2011, 31:650-658.
131. Reddy D.S., Ramanathan G. Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Epilepsy Behav. 2012, 25:92-97.
132. Reddy D.S., Rogawski M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J. Pharmacol. Exp. Ther. 2000, 294:909-915.
133. Reddy D.S., Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 2000, 295:1241-1248.
134. Reddy D.S., Rogawski M.A. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001, 42:303-310.
135. Reddy D.S., Rogawski M.A. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009, 6:392-401.
136. Reddy D.S., Zeng Y.C. Effect of neurosteroid withdrawal on spontaneous recurrent seizures in a rat model of catamenial epilepsy. FASEB J. 2007, 21(6):A1179-A11179.
137. Reddy D.S., Kim H.Y., Rogawski M.A. Neurosteroid withdrawal model of perimenstrual catamenial epilepsy. Epilepsia 2001, 42:328-336.
138. Reddy D.S., Castaneda D.C., O'Malley B.W., Rogawski M.A. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J. Pharmacol. Exp. Ther. 2004, 310(1):230-239.
139. Reddy D.S., Gangisetty O., Briyal S. Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Neuropharmacology 2010, 59:573-581.
140. Reddy D.S., Gould J., Gangisetty O. A mouse kindling model of perimenstrual catamenial epilepsy. J. Pharmacol. Exp. Ther. 2012, 341:784-793.
141. Rinta S., Airas L., Elovaara I. Is the modulatory effect of pregnancy in multiple sclerosis associated with changes in blood apoptotic molecules?. Acta Neurol. Scand. 2010, 122:168-174.
142. Roger V.L., Go A.S., Lloyd-Jones D.M. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
143. Rojas A., Jiang J., Ganesh T., Yang M.S., Lelutiu N., Gueorguieva P., Dingledine R. Cyclooxygenase-2 in epilepsy. Epilepsia 2014, 55:17-25.
144. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
145. Sakata A., Mogi M., Iwanami J., Tsukuda K., Min L.J., Jing F., Ohshima K., Ito M., Horiuchi M. Female type 2 diabetes mellitus mice exhibit severe ischemic brain damage. J. Am. Soc. Hypertens. 2011, 5:7-11.
146. Seifert H.A., Hall A.A., Chapman C.B., Collier L.A., Willing A.E., Pennypacker K.R. A transient decrease in spleen size following stroke corresponds to splenocyte. J. Neuroimmune Pharmacol. 2012, 7(4):1017-1024.
147. Selvamani A., Sohrabji F. Reproductive age modulates the impact of focal ischemia on the forebrain as well as the effects of estrogen treatment in female rats. Neurobiol. Aging 2010, 31:1618-1628.
148. Selvamani A., Sohrabji F. The neurotoxic effects of estrogen on ischemic stroke in older female rats is associated with age-dependent loss of insulin-like growth factor-1. J. Neurosci. 2010, 30:6852-6861.
149. Shao B., Cheng Y., Jin K. Estrogen, neuroprotection and neurogenesis after ischemic stroke. Curr. Drug Targets 2012, 13:188-198.
150. Sicotte N.L., Liva S.M., Klutch R., et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 2002, 52:421-428.
151. Sieve A.N., Steelman A.J., Young C.R., Storts R., Welsh T.H., Welsh C.J.R., Meagher M.W. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice. J. Neuroimmunol. 2004, 155:103-118.
152. Silva G.S., Lima F.O., Camargo E.C., Smith W.S., Lev M.H., Harris G.J., Halpern E.F., Koroshetz W., Furie K.L. Gender differences in outcomes after ischemic stroke: role of ischemic lesion volume and intracranial large-artery occlusion. Cerebrovasc. Dis. 2010, 30:470-475.
153. Simpkins J.W., Rajakumar G., Zhang Y.Q., Simpkins C.E., Greenwald D., Yu C.J., Bodor N., Day A.L. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg. 1997, 87:724-730.
154. Simpkins J.W., Yi K.D., Yang S.H., Dykens J.A. Mitochondrial mechanisms of estrogen neuroprotection. Biochim. Biophys. Acta 2010, 1800:1113-1120.
155. Singh M., Su C. Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy. Brain Res. 2013, 1514:98-106.
156. Smith R., Studd J.M. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and menstrual cycle. J. R. Soc. Med. 1992, 85:612-613.
157. Smith S.S., Shen H., Gong Q.H., Zhou X. Neurosteroid regulation of GABA-A receptors: focus on the alpha4 and delta subunits. Pharmacol. Ther. 2007, 116:58-76.
158. Smith-Bouvier D.L., Divekar A.A., Sasidhar M., Du S., Tiwari-Woodruff S.K., King J.K., Arnold A.P., Singh R.R., Voskuhl R.R. A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med. 2008, 205:1099-1108.
159. Sohrabji F., Bake S. Age-related changes in neuroprotection: is estrogen pro-inflammatory for the reproductive senescent brain?. Endocrine 2006, 29:191-197.
160. Soldan S., Alvarez Retuerto A., Sicotte N., Voskuhl R. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol. 2003, 171:6267-6274.
161. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
162. Soucy G., Boivin G., Labrie F., Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J. Immunol. 2005, 174:6391-6398.
163. Spence R.D., Voskuhl R.R. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front. Neuroendocrinol. 2012, 33:105-115.
164. Spence R.D., Hamby M.E., Umeda E., Itoh N., Du S., Wisdom A.J., Cao Y., Bondar G., Lam J., Ao Y., Sandoval F., Suriany S., Sofroniew M.V., Voskuhl R.R. Neuroprotection mediated through estrogen receptor in astrocytes. Proc. Natl. Acad. Sci. 2011, 108:8867-8872.
165. Spence R.D., Wisdom A.J., Cao Y., Hill H.M., Mongerson C.R.L., Stapornkul B., Itoh N., Sofroniew M.V., Voskuhl R.R. Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurones. J. Neurosci. 2013, 33:10924-10933.
166. Stein D.G. Progesterone in the treatment of acute traumatic brain injury: a clinical perspective and update. Neuroscience 2011, 191:101-106.
167. Stuart M., Bergstrom L. Pregnancy and multiple sclerosis. J. Midwifery Womens Health 2011, 56:41-47.
168. Sutton C., Brereton C., Keogh B., Mills K.H.G., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
169. Suuronen T., Nuutinen T., Huuskonen J., Ojala J., Thornell A., Salminen A. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm. Res. 2005, 54:194-203.
170. Theiler M. Spontaneous encephalomyelitis of mice - a new virus. Science 1934, 80:122.
171. Thompson C., Powrie F. Regulatory T cells. Curr. Opin. Pharmacol. 2004, 4:408-414.
172. Tiwari-Woodruff S., Voskuhl R. Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J. Neurol. Sci. 2009, 286:81-85.
173. Tiwari-Woodruff S., Morales L.B.J., Lee R., Voskuhl R.R. Differential neuroprotective and antiflammatory effects of estrogen receptor (ER) alpha and ER beta ligand treatment. Proc. Natl. Acacd. Sci. 2007, 104:14813-14818.
174. Toung T.K., Hurn P.D., Traystman R.J., Sieber F.E. Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke 2000, 31:2701-2706.
175. Towfighi A., Saver J.L., Engelhardt R., Ovbiagele B. A midlife stroke surge among women in the United States. Neurol. 2007, 69:1898-1904.
176. Tuveri A., Paoletti A.M., Orrù M., Melis G.B., Marotto M.F., Zedda P., Marrosu F., Sogliano C., Marra C., Biggio G., Concas A. Reduced serum level of THDOC, an anticonvulsant steroid, in women with perimenstrual catamenial epilepsy. Epilepsia 2008, 49:1221-1229.
177. Valor L., Teijeiro R., Aristimuño C., Faure F., Alonso B., de Andres C., Tejera M., Lopez-Lazareno N., Fernandez-Cruz E., Sanchez-Ramon S. Estradiol-dependent perforin expression by human regulatory T-cells. Eur. J. Clin. Invest. 2011, 41:357-364.
178. Vegeto E., Benedusi V., Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 2008, 29:507-519.
179. Verrotti A., Latini G., Manco R., De Simone M., Chiarelli F. Influence of sex hormones on brain excitability and epilepsy. J. Endocrinol. Invest. 2007, 30(9):797-803.
180. Vezzani A., Aronica E., Mazarati A., Pittman Q.J. Epilepsy and brain inflammation. Exp. Neurol. 2013, 244:11-21.
181. Viglietta V., Baechder-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+ CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 2004, 199:1285-1291.
182. Voskuhl R.R., Pitchekian-Halabi H., MacKenzie-Graham A., McFarland H.F., Raine C.S. Gender differences in autoimmune demyelination in the mouse: implications for multiple sclerosis. Ann. Neurol. 1996, 39:724-733.
183. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., Kotchen T., Curb J.D., Black H., Rossouw J.E., Aragaki A., Safford M., Stein E., Laowattana S., Mysiw W.J., WHI Investigators Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003, 289:2673-2684.
184. Weinshenker B.G. Natural history of multiple sclerosis. Ann. Neurol. 1994, 36(Suppl.):S6-S11.
185. Welsh C.J.R., Tonks P., Borrow P., Nash A.A. Theiler's virus: an experimental model of virus-induced demyelination. Autoimmunity 1990, 6:105-112.
186. Whitacre C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001, 2:777-780.
187. Wingerchuk D.M., Lucchinetti C.F., Noseworthy J.H. Multiple sclerosis: current pathophysiological concepts. Lab. Invest. 2001, 81:263-281.
188. Wu X., Gangisetty O., Carver C.M., Reddy D.S. Estrous cycle regulation of extrasynaptic δ-containing GABAA receptor-mediated tonic inhibition and limbic epileptogenesis. J. Pharmacol. Exp. Ther. 2013, 346:146-160.
189. Yang S.H., Liu R., Wu S.S., Simpkins J.W. The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Ann. N. Y. Acad. Sci. 2003, 1007:101-107.
190. Yates M.A., Li Y., Chlebeck P., Proctor T., Vandenbark A.A., Offner H. Progesterone treatment reduces disease severity and increases IL-10 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2010, 220:136-139.
191. Young E.E., Sieve A.N., Vichaya E.G., Carcoba L.M., Young C.R., Ambrus A., Storts R., Welsh C.J.R., Meagher M.W. Chronic restraint stress during early Theiler's virus infection exacerbates the subsequent demyelinating disease in SJL mice: II. CNS disease severity. J. Neuroimmunol. 2010, 220:79-89.
192. Zhang B., Subramanian S., Dziennis S., Jia J., Uchida M., Akiyoshi K., Migliati E., Lewis A.D., Vandenbark A.A., Offner H., Hurn P.D. Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J. Immunol. 2010, 184:4087-4094.
193. Zhang Z., Yang R., Cai W., Bai Y., Sokabe M., Chen L. Treatment with progesterone after focal cerebral ischemia suppresses proliferation of progenitor cells but enhances survival of newborn neurons in adult male mice. Neuropharmacology 2010, 58(6):930-939.